Impel Pharmaceuticals Inc.
IMPLNASDAQHealthcare
$0.04
$-0.02(-27.27%)
Market Cap$956000
P/E Ratio—
52W High$4.2
52W Low$0.0212
Impel Pharmaceuticals Inc. (IMPL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMPL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $12.65M | $0.67M | $0.00M | $0.00M |
| Cost of Revenue | $6.50M | $0.69M | $0.00M | $0.00M |
| Gross Profit | $6.16M | ($0.02M) | $0.00M | $0.00M |
| Gross Margin %(computed) | 48.66% | -3.44% | — | — |
| Operating Expenses | ||||
| R&D Expenses | $11.46M | $20.56M | $27.29M | $28.81M |
| G&A Expenses | $77.89M | $50.90M | $18.05M | $12.75M |
| Total Operating Expenses | $89.34M | $71.46M | $45.33M | $41.57M |
| Operating Income | ($83.18M) | ($71.49M) | ($45.33M) | ($41.57M) |
| Operating Margin %(computed) | -657.48% | — | — | — |
| Interest Income | $10.58M | $2.25M | $0.00M | $0.42M |
| Interest Expense | $13.84M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($106.31M) | ($76.53M) | ($45.80M) | ($41.83M) |
| Income Tax Expense | $23.13M | $0.00M | $0.00M | $0.03M |
| Net Income | ($129.44M) | ($76.54M) | ($45.80M) | ($41.86M) |
| Net Margin %(computed) | — | — | — | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-5.52 | $-5.24 | $-3.49 | $-3.19 |
| Wtd Avg Shares | 23.45M | 14.60M | 13.14M | 13.14M |
| EBITDA | ($91.28M) | ($70.40M) | ($44.26M) | ($40.84M) |
| EBITDA Margin %(computed) | -721.44% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Impel Pharmaceuticals Inc. data
About Impel Pharmaceuticals Inc. (IMPL) Income Statement
Impel Pharmaceuticals Inc. (IMPL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, IMPL reported revenue of $0.01B, gross profit of $0.01B (gross margin 48.66%), and net income of ($0.13B) — a net profit margin of -1023.08%.
Frequently asked questions
IMPL · 4 questionsImpel Pharmaceuticals Inc. (IMPL) reported revenue of $0.01B for 2022, up 1794.0% year-over-year.
IMPL revenueIMPL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09